Get a Quote

Dapagliflozin Propanediol
CAS NO.: 461432-26-8
Chemical Formula: C21H25ClO6
Molecular Weight: 408.8730
DMF&GMP status: Please contact us for more details.
Description:
Dapagliflozin is an oral diabetes medicine that helps control blood sugar levels. Dapagliflozin works by helping the kidneys get rid of glucose from your bloodstream. Dapagliflozin is used together with diet and exercise to treat type 2 diabetes. Dapagliflozin is not for treating type 1 diabetes. Dapagliflozin is indicated for the management of diabetes mellitus type 2, and functions to improve glycemic control in adults when combined with diet and exercise. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor, which prevents glucose reabsorption in the kidney. Using dapagliflozin leads to heavy glycosuria (glucose excretion in the urine), which can lead to weight loss and tiredness. Dapagliflozin was approved by the FDA on Jan 08, 2014.
Approvals
Active Ingredient Dosage Form; Route Strength Proprietary Name Applicant
DAPAGLIFLOZIN PROPANEDIOLTABLET; ORALEQ 10MG BASEFARXIGAASTRAZENECA AB
DAPAGLIFLOZIN PROPANEDIOL TABLET; ORAL EQ 5MG BASE FARXIGA ASTRAZENECA AB
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE TABLET; EXTENDED RELEASE; ORAL EQ 10MG BASE; 1GM XIGDUO XR ASTRAZENECA AB
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE TABLET; EXTENDED RELEASE; ORAL EQ 10MG BASE; 500MG XIGDUO XR ASTRAZENECA AB
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE TABLET; EXTENDED RELEASE; ORAL EQ 5MG BASE; 1GM XIGDUO XR ASTRAZENECA AB
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHL TABLET EXTENDED RELEASE; ORAL EQ 5MG BASE; 500MG XIGDUO XR ASTRAZENECA AB
Patent Data
Patent No. Patent Expiration Drug Substance Claim Drug Product Claim Patent Use Code
64141264-Oct-20YYU - 493
6515117 4-Oct-20 Y Y U - 493
6936590 4-Oct-20     U - 493
7851502 19-Aug-28   Y  
7919598 16-Dec-29 Y    
8221786 21-Mar-28   Y  
8361972 21-Mar-28     U - 493
8501698 20-Jun-27         Y U - 493
8685934 26-May-30   U – 1522
8716251 21-Mar-28 Y  
9198925 4-Oct-20   U - 493
Exclusive Data
Exclusivity Code Exclusivity Expiration
NCE 01/08/2019
M - 157 03/11/2018